Ocean Biomedical, Inc. (OCEA )

Currency in USD Disclaimer
$1.08 +$0.17 (18.27%)
Closed 10/15/2024
$0.92
$1.13
$0.52
$7.79

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol OCEA
  • Company Ocean Biomedical, Inc.
  • Price $1.08
  • Changes Percentage 18.27
  • Change 0.1668
  • Day Low $0.92
  • Day High $1.13
  • Year High $7.79
  • Year Low $0.52
  • Market Cap $37,420,972
  • Price Avg 50 EMA (D) $1
  • Price Avg 200 EMA (D) $1.51
  • Exchange NASDAQ
  • Volume 209,360
  • Average Volume 57,992
  • Open $0.93
  • Previous Close $0.91
  • EPS -3
  • PE -0.36
  • Earnings Announcement 2024-11-27 12:00:00
  • Shares Outstanding $34,649,048

Company brief: OCEAN BIOMEDICAL, INC. (OCEA )

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

OCEA Corporation News

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

October 15, 2024 at 7:30 am ET

globenewswire.com -- This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as we...

Income Statement